Grb7 is an adapter-type signaling protein, which is recruited via its SH2 domain to a variety of receptor tyrosine kinases (RTKs), including ErbB2 and ErbB3. It is overexpressed in breast, esophageal, and gastric cancers, and may contribute to the invasive potential of cancer cells. Molecular interactions involving Grb7 therefore provide attractive targets for therapeutic intervention. We have utilized phage display random peptide libraries as a source of small peptide ligands to the SH2 domain of Grb7. Screening these libraries against purified Grb7 SH2 resulted in the identification of Grb7-binding peptide phage clones that contained a nonphosphorylated Tyr-X-Asn (YXN) motif. The tyrosinephosphorylated form of this motif is characteristic of Grb7 SH2 domain binding sites identified in RTKs and other signaling proteins such as Shc. Peptides that are non-phosphorylated have greater potential in the development of therapeutics because of the instability of a phosphate group in vivo. Using a biased library approach with this conserved YXN motif, we identified seven different peptide phage clones, which bind specifically to the SH2 domain of Grb7. These peptides did not bind to the SH2 domain of Grb2 (which also selects for Asn at pY ؉2 ) or Grb14, a closely related family member. The cyclic structure of the peptides was required to bind to the Grb7 SH2 domain. Importantly, the synthetic Grb7-binding peptide G7-18 in cell lysates was able to specifically inhibit the association of Grb7 with the ErbB family of RTKs, in particular ErbB3, in a dose-dependent manner. These peptides will be useful in the development of targeted molecular therapeutics for cancers overexpressing Grb7 and in the development of Grb7-specific inhibitors to gain a complete understanding of the physiological role of Grb7.
SH2 domains are found in a large number of proteins and mediate signal transduction pathways associated with tyrosine kinase activity by binding to specific phosphorylated tyrosine residues on target proteins. These domains, ϳ100 amino acids long, serve a critical role by transmitting signals within a cell, act as adapters between receptors and downstream signaling molecules, and regulate the kinase activity of specific proteins (1, 2) . These domains are attractive targets for developing targeted therapeutics, especially in the area of oncology and immunology. Our laboratory was the first to identify a nonphosphorylated ligand to the SH2 domain of Grb2 (3), and several other groups have also reported ligands targeting the SH2 domains of Grb2 (4, 5) , pp60c-src (6 -9) , and p56lck (10, 11) . Our interests are to target SH2 domain proteins that play a role in signaling by the ErbB tyrosine kinase family of receptors, which comprises EGFR, ErbB2, ErbB3, and ErbB4. Grb7 is an especially promising cancer target because the encoding gene maps closely to the ErbB2 gene and is found co-amplified in a subset of breast cancers (12) . In addition, Grb7 is overexpressed with ErbB2 in breast, esophageal, and gastric cancers (12) (13) (14) . The importance of ErbB2 in breast cancer is well established. ErbB2 is a tyrosine kinase receptor that is 1) overexpressed on the tumor cells of ϳ30% of breast cancer patients and in more than half of in situ ductal carcinomas, which suggests that ErbB2 overexpression may be an important initiating event in breast cancer; 2) associated with poor prognosis; and 3) found only minimally on normal cells (15) (16) (17) . Blocking the function of ErbB2 inhibits proliferation of cancer cells as demonstrated in preclinical (18, 19) and clinical studies (20, 21) . In addition, co-expression of Grb7 with ErbB2 was detected in 31% of esophageal carcinomas and was significantly correlated with extramucosal tumor invasion (14) . Moreover, Grb7 is co-expressed with ErbB3 and ErbB4, which are known to heterodimerize with ErbB2, in a subgroup of human breast cancer cell lines (22) .
The SH2 domain of Grb7 binds to an intracellular phosphorylated tyrosine residue of ErbB2 as well as to specific phosphotyrosines of other receptors such as ErbB3 (22) , ErbB4 (22) , platelet-derived growth factor receptor (23) , focal adhesion kinase (24) , c-Kit stem cell factor receptor (25, 26) , Ret (26) , and Tek/Tie (27) . The Grb7 SH2 domain also binds to the protein tyrosine phosphatase SHPTP2 (28) and the adapter protein SHC (12) . The functional consequences of the association of Grb7 with its physiological ligands have not been completely elucidated. However, the importance of Grb7 in tumor progression has been suggested by several studies (14, 24, 29, 30) . In one recent study, histologic expression of Grb7 in primary squamous cell esophageal tumors at the time of surgical resection showed Grb7 to be overexpressed in 14 of 31 esophageal carcinomas as compared with adjacent normal mucosa. The overexpression of Grb7 in these histological sections was sig-nificantly correlated with the presence of lymph node metastases (30) . In another study, inducible Grb7 overexpression in NIH3T3 cells increased cell migration toward fibronectin, whereas overexpression of its SH2 domain inhibited cell migration (24) . Likewise, overexpression of Grb7, and not a Grb7 mutant where the SH2 and GM domains were eliminated, stimulated cell migration in CHO cells (31) . Furthermore, in an esophageal cancer line, down-regulation of Grb7 using antisense technology inhibited the invasive properties of the cells (29) . Another promising feature of Grb7 as a tumor target is its limited tissue distribution, which is unlike that of many other SH2 domain-containing proteins which are ubiquitously expressed (2) . Having limited tissue distribution is advantageous for targeting therapeutics to cancer cells. The fact that Grb7 is associated with tumor-related molecules and has been demonstrated to have a direct role in cancer cell migration makes it a potentially important therapeutic target.
Phage display libraries have been used extensively to identify peptide ligands for a variety of molecular targets (32) (33) (34) . These libraries are an abundant source of potential small ligands to tumor targets and other macromolecules. Even though a variety of systems have been developed, the most common phage display system expresses the fusion protein on the minor coat protein, pIII (35) , or the major coat protein, pVIII (36) . There are many small peptides that have proven to be useful in tumor targeting and anti-cancer therapies, such as those that specifically bind to the vasculature of tumors in vivo and deliver cytotoxic agents specifically to tumor cells (37); 2) specifically bind and regulate estrogen receptor ␣ transcriptional activity, which can be used in the development of novel treatments for tamoxifen-refractory breast cancers (38) ; and 3) specifically bind to type IV collagenase/gelatinase matrix metalloproteinases and inhibit the migration of human endothelial cells and tumor cells, which may prove useful in tumor targeting and anti-cancer therapies (39) .
Peptides identified from phage display libraries can be modified, if necessary, to obtain an intracellularly stable, cell permeable, and higher affinity peptide that maintains specific binding to its target. These modifications can be achieved utilizing a homologous-analog and/or peptidomimetics approach to confer desirable pharmaceutical properties of stability, affinity, and specificity (40 -43) . Peptides can also be modified with the addition of a membrane translocating sequence for delivery into a cell (44 -48) . In addition, a structure-based approach can be used for optimization of the targeting properties of a peptide, such as affinity, by studying the peptide or the peptide complexed to its target (4, 6, 49, 50) .
Using phage display, we have identified the first non-phosphorylated peptides that are highly selective for the Grb7 SH2 domain compared with Grb2 or Grb14 SH2 domains. In addition, one of the Grb7-binding peptides is able to effectively block Grb7 from binding to the ErbB family of RTKs.
1 These Grb7-binding peptides will be further evaluated as lead compounds for drugs that target diseases where Grb7 is overexpressed and may provide useful tools for the elucidation of Grb7 function.
EXPERIMENTAL PROCEDURES

Construction of the Random and YXN-biased Peptide Phage Libraries-
The peptide libraries used in these studies were constructed in the fUSE5 gene III phage display system (51) . The fUSE5 vector and Escherichia coli host strains (K91 Kan and MC1061FЈ) were the generous gift of Dr. George Smith at the University of Missouri (51) . The half-site cloning method used by Cwirla et al. (52) was employed in construction of these libraries. The two half-site oligos 5Ј-TCCGC-CAGCCCCGT-3Ј (GS5Ј) and 5Ј-CGGCCCCGCCTCC-3Ј(GS3Ј) are complementary to the 5Ј-and 3Ј-ends of the peptide insert-encoding oligonucleotide. The random peptide encoding oligonucleotide has the following sequence: 5ЈpGGGCTGGCGGA(NNK) 4 TGC(NNK) 10 TGC-(NNK) 4 GGAGGCGGGGCCGCTG 3Ј (referred to as ON-10). The YXNbiased peptide encoding oligonucleotide has the following sequence: GGGCTGGCGGA(NNK) 4 TGC(NNK) 4 TAYEFJAAY(NNK) 3 TGC-(NNK) 4 GGAGGCGGGGCCGCTG (referred to as ON-YXN) where N refers to equal amounts of G, A, T or C; K refers to equal amounts of G or T; Y refers to equal amounts of T and C; E refers to 62.5% G, 12.5% A, 12.5% C, and 12.5% T; F refers to 37.5% A, 37.5% C, 12.5% G, and 12.5% T; and J refers to 37.5% G, 37.5% T, 12.5% A, and 12.5% C. Oligos GS5Ј, GS3Ј, and ON-10 were synthesized by the University of Vermont Molecular Genetics Oligo Synthesis Facility, and the YXN-biased oligonucleotide by Biosynthesis, Inc. (Lewisville, Texas). The annealing reaction for the random library was carried out by mixing 219 pmol of GS5Ј, 219pmol GS3Ј, and 10.96 pmol of ON-10. The annealing reaction for the YXN-biased library contained 144 pmol of GS5Ј, 144 pmol of GS3Ј, and 7.5 pmol of ON-YXN. After the annealing reactions were carried out to generate double-stranded termini, the non-annealed single stranded half-site oligos were removed using QIAquick Clean-up Kit (Qiagen), eluting in 36 l of 10 mM Tris-HCl buffer, pH 8.5. The SfiI-digested fUSE5 phage vector (13.7 g for the random peptide library and 15 g for the YXN-biased library) were ligated to the annealed oligos in a 1-ml reaction containing T4 DNA Ligase (Invitrogen) (1 unit/g of vector) overnight at 15°C followed by heat inactivation at 65°C for 10 min. The ligation reactions were ethanol-precipitated with pellet paint co-precipitant (Novagen) for 3 h at Ϫ20°C, resuspended in 60 l of water, and heated at 50°C for 5 min to thoroughly dissolve the DNA. The ligations were transformed into freshly prepared electrocompetent E. coli (MC1061FЈ) cells. Sixty electrotransformations, each containing 40 l of cells, were performed at 1.7 kV. After transformation, the cells were collected in 2 ml of SOC medium and grown for an hour at 37°C, 220 rpm. After the hour of non-selective growth, all transformation reactions were pooled, centrifuged at 8000 rpm for 10 min, and resuspended in 10 ml of SOC medium. An aliquot of the transformations was plated onto an LB/tetracycline plate to determine the original number of transformants. The pools of transformants were plated on Pyrex dishes (11 ϫ 7 inches) containing 2ϫ YT/tetracycline/ streptomycin (1 ml per dish). The dishes were incubated at 37°C overnight to allow and produce thousands of copies of each peptide phage particle library member.
Purification of Glutathione S-Transferase (GST) Fusion ProteinsThe SH2 domain constructs for Grb7, Grb14, Grb7 ␤D5/␤D6, and Grb2 were provided by Dr. Roger Daly. The construction of these plasmids have been described by Janes et al. (53) and Lowenstein et al. (54) . These proteins were expressed in a GST fusion bacterial expression system using the pGEX-2T expression vector (Amersham Biosciences, Inc.) and purified from isopropyl-␤-D-thiogalactopyranoside-induced bacterial cultures as described previously (55) . Purity was determined by SDS-PAGE. Protein concentration was determined by Bradfordbased protein assay (Bio-Rad).
Peptide Phage Library Screening-The libraries were amplified so that there were ϳ1000 transforming units of each peptide phage representing 200 library equivalents. The amplified phage were infected into K91/Kan cells, plated onto five 2ϫ YT agar dishes (11 ϫ 7 inches) containing 40 g/ml tetracycline, incubated overnight at 30°C, and harvested in 1ϫ phosphate-buffered saline with a prokaryotic protease inhibitor mixture (1:1000)(Sigma) by sweeping the bacteria off the agar with a bent glass rod. The bacterial cell suspension was centrifuged at 8000 rpm for 10 min at 4°C, and the supernatant was filtered through a 0.22-m polyethersulfone (PES) filter. The filtrate was incubated for 30 min on ice with 0.15 volume of polyethylene glycol/NaCl to precipitate the phage and centrifuged at 9000 rpm, 20 min, 4°C. The phage pellet was resuspended in 1ϫ phosphate-buffered saline with a prokaryotic protease inhibitor mixture. GST-binding peptide phage were subtracted from the library by preincubation of the library with 2 g of GST immobilized on 20 l of glutathione-Sepharose (Amersham Biosciences, Inc.). The phage were screened by adding them to 12 g of purified GST⅐Grb7 SH2 immobilized onto 20 l of glutathione-Sepharose and incubated for 2 h on a nutator at 25°C. The unbound phage were removed by washing five times with 1ϫ phosphate-buffered saline with a prokaryotic protease inhibitor mixture. Phage binders were eluted twice with a low pH (2.3) buffer followed by two elutions with a high pH (12) buffer. K91/Kan cells were then infected with the pooled phage elutions, and a small aliquot was plated to determine the total amount of phage particles bound to the targets. The remaining phage were amplified overnight, harvested, screened, and eluted as described above. To determine the amount of enrichment after the second and third rounds of panning, half of the pre-cleared phage were added to fresh GST immobilized on glutathione beads to determine the amount of phage binding GST-glutathione-Sepharose compared with GST⅐Grb7 SH2 glutathione-Sepharose. Three rounds of screening were carried out before clones were sequenced or tested in an ELISA.
DNA and Amino Acid Sequence Determination of Harvested PhageIsolated peptide phage-infected E. coli colonies were grown in 5 ml of LB/tetracycline broth. The double-stranded phage replicative form DNA was isolated using the QIAprep Spin Miniprep kit (Qiagen). The following sequencing primer designed by George Smith was used to sequence the random insert in the fUSE5 vector: 5Ј-CCC TCA TAG TTA GCG TAA CG-3Ј (51). The sequence reactions were carried out using BigDye Version 1 Dye Terminator kit (PerkinElmer Life Sciences). The sequencing reactions and automated DNA sequencing were performed in the Vermont Cancer Center DNA Analysis Facility.
The amino acid sequences of peptides displayed by peptide phage were deduced from the DNA sequence of the corresponding phage clones. Consensus sequence identification was performed by visual inspection and with the ClustalW alignment program.
Reverse Phage ELISA-A reverse phage ELISA was used to evaluate the ability of individual phage clones to bind to Grb7 SH2 (32, 56) . Briefly, protein targets (5 g/ml) were added to a 96-well Maxisorp plate (Nunc) plate precoated with anti-GST polyclonal antibody (1 g/ml final concentration) (Amersham Biosciences, Inc.) and blocked with casein in Tris-buffered saline (Pierce). The peptide phage were concentrated with polyethylene glycol/NaCl precipitation methods (51), added to each well (1 ϫ 10 7 Ϫ1 ϫ 10 8 phage/well), and incubated for 2 h. at room temperature. Unbound phage were removed with 0.1% TweenTris-buffered saline buffer, and phage were detected with horseradish peroxidase-conjugated anti-M13 monoclonal antibody (1:1000) (Amersham Biosciences, Inc.) and 2,2Ј-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) substrate (Calbiochem). Plates were read at A 405 .
Construction of Modified Peptide Phage Clones-To determine whether the four flanking amino acids adjacent to the cysteine residues and the cyclic structure were required for binding the Grb7 SH2 domain, modified peptide phage clones were created. DNA oligos to encode for four different modifications (see "Results" for a description of these modifications) of the Grb7-binding peptide phage were synthesized (Biosynthesis, Inc.) with the following sequences: G7-8-NA ϭ 5Ј GGG CTG GCG GA TGC GTT TTC TGG GGT TAC GCT AAC GAC TGG CTG TGC GGA GGC GGG GCC GCT G 3Ј; G7-8-Ser ϭ 5Ј GGG CTG GCG GA GGT GTT TCC AAC TCC GTT TTC TGG GGT TAC GCT AAC GAC TGG CTG TCC TCC GAC TAC TCC GGA GGC GGG GCC GCT G 3Ј; G7-8-Val ϭ 5Ј GGG CTG GCG GA GGT GTT TCC AAC GTT GTT TTC TGG GGT TAC GCT AAC GAC TGG CTG GTT TCC GAC TAC TCC GGA GGC GGG GCC GCT G 3Ј; G7-8-NA-Ser ϭ 5Ј GGG CTG GCG GA TCC GTT TTC TGG GGT TAC GCT AAC GAC TGG CTG TCC GGA GGC GGG GCC GCT G 3Ј. The ligation reaction contained 0.08 pmol of annealed product into 0.032 pmol (200 ng) of fUSE5 vector using the same half-site cloning method described above. After the ligation reaction was electroporated into MC1061FЈ E. coli cells, the DNA was sequenced to confirm the presence of the correct insert. The expressed peptide phage were tested for binding to Grb7 SH2 in a reverse phage ELISA as described above.
Competitive Reverse Phage ELISA-The relative ability of the free synthetic Grb7-binding peptides to inhibit the interaction between the Grb7-binding peptide phage and Grb7 SH2 was determined in a competitive reverse phage ELISA. This method was based on work previously described by Barrett et al. (57) and Carcamo et al. (58) . Purified GST⅐Grb7 SH2 (5 g/ml) was added to a plate precoated with anti-GST polyclonal antibody and blocked with casein in Tris-buffered saline. The peptide phage were concentrated by polyethylene glycol/NaCl precipitation, as described above. The synthetic peptides were mixed at different concentrations (1, 10, 100 M) with peptide phage (1 ϫ 10 6 transforming units/well) before adding to GST⅐Grb7 SH2 bound to the 96-well plate. Bound phage were detected as described above. Percent inhibition is calculated as follows: 100 -KYFR-amide, Cys-5/Cys-16 disulfide cyclized) was synthesized using Fmoc chemistry protocols, using the 5-(4-aminomethyl-3,5-dimethoxyphenoxy)-valeric acid resin. The fully deprotected peptides (0.1 mmol peptide/150 ml pH 7-8 ammonium acetate buffer) were cyclized with oxygen gas bubbled into the solution for 24 h at room temperature. The two thioether-cyclized analogs, G7-8NATE (VFW-GYANDWLC-amide) and G7-18NATE (WFEGYDNTFPC-amide) were synthesized according to methodologies previously described (59, 60) . Briefly, the peptides were synthesized on a PAL amide resin using standard solid phase Fmoc chemistry-based protocols. The resin bound side chain protected peptides were N-terminally chloroacetylated with in situ-generated chloroacetic anhydride. The peptides were removed from the resin and fully deprotected with trifluoroacetic acid containing thioanisole and ethanedithiol. The crude peptides were cyclized by intramolecular nucleophilic displacement of the N-terminal chloro group by the C-terminal cysteine side chain thiol functionality in an aqueous solution (0.1 mmol of peptide in 120 ml of water) maintained at pH 8 -8.5 with triethylamine at room temperature for 6 h. The peptides were purified by reverse phase high pressure liquid chromatography in water/acetonitrile (0.05% trifluoroacetic acid) gradient. The purity and identity of the peptides were confirmed by fast atom bombardment mass spectroscopy (unit resolution, glycerol matrix) on a VG Analytical 7070 EHF mass spectrometer.
Cell Lysis and Immunoprecipitation Inhibition Assays-Whole cell extracts were made from the cell line SK-BR-3 (American Type Culture Collection). Briefly, the cells were grown until 70 -80% confluence in T-75 or T-150 flasks. After overnight starvation in serum-free media, the cells were stimulated with 0.08 g/ml recombinant heregulin-␤1 (R&D Systems) for 10 min at 37°C. After stimulation, the cells were washed twice with phosphate-buffered saline, lysed with ice-cold lysis buffer (1% Triton X-100, 50 mM Hepes, 50 mM NaCl, 10% glycerol, 1.5 mM MgCl 2 , 1 mM EGTA, 10 mM sodium pyrophosphate, 20 mM NaF, 10 g/ml aprotinin, 10 g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate) for 10 min on ice, and collected with a cell scraper. The insoluble debris was separated by microfuging lysates for 5 min at 4°C and 13,000 rpm ,and the supernatant was collected and frozen at Ϫ80°C. Protein concentration of the lysate was determined by a Bradford-based protein assay (Bio-Rad). The stimulated SK-BR-3 cell lysate (0.5-1 mg) was incubated with 20 l of protein A-Sepharose to preclear the lysates. The precleared lysate was incubated with increasing amounts of synthetic G7-18NATE peptide or no peptide (control) for 1 h at 4°C and then immunoprecipitated with 2 g of anti-Grb7 polyclonal antibody (N-20, Santa Cruz Biotechnology) overnight at 4°C. The immunocomplexes were collected by incubation with 50 l of protein A-Sepharose 4B beads (Zymed Laboratories Inc.) for 1 h at 4°C. In the case of Grb2 immunoprecipitations, 2 g of Sepharose-conjugated anti-Grb2 polyclonal antibody (C-23, Santa Cruz Biotechnology) were used. The immunocomplexes were collected by centrifugation, washed five times in cold lysis buffer, and eluted with sample buffer at 100°C for 5 min. The immunocomplexes were then subjected to Western blot analysis on a 7.5% SDS-polyacrylamide gel using the following primary antibodies: horseradish peroxidase-conjugated anti-phosphotyrosine recombinant antibody (BD Transduction Laboratories), anti-ErbB3 polyclonal antibody (Santa Cruz Biotechnology), and anti-Grb7 polyclonal antibody. Horseradish peroxidase-protein A (Zymed Laboratories Inc.) was used to identify ErbB3, and all bands were detected with an ECL chemiluminescence kit (Amersham Biosciences, Inc.). Densitometric analyses of the autoradiographs were performed using the Fluor-S MultiImager with Quantity One 4.2.1 software (Bio-Rad).
RESULTS
Identification of Grb7 SH2 Domain-binding Peptides by
Screening a Random Peptide Phage Display Library-We constructed a random peptide phage display library which displays 18 random amino acids with two cysteine residues fixed at positions 5 and 16 (X 4 CX 10 CX 4 ; X represents any amino acid). The oligos used to construct the library employ NNK, a cloning scheme commonly used in phage display to eliminate the potential for two stop codons that still allows for encoding of all 20 amino acids. The cysteines allow the formation of a disulfide bond that results in display of a constrained 12-residue loop. Peptides that are conformationally constrained often possess a higher affinity for a target than the linear counterparts. The four amino acids on the N and C termini of the loop were included to add a linear component to the cyclic peptide, which might allow the peptide to anchor itself with greater affinity onto the target. This random fUSEV peptide library contained 2.0 ϫ 10 7 different peptides. DNA sequencing of the N-terminal region of gene III of randomly chosen phage clones confirmed the presence of correct inserts.
After three rounds of screening the random peptide phage display library with purified GST⅐Grb7 SH2, we observed excellent enrichment of Grb7-binding peptide phage because 10 times more enriched phage bound to GST⅐Grb7 SH2 compared with GST alone. Gene III DNA of 40 clones was sequenced, and the amino acid sequences of the displayed peptides was deduced. A YXN motif was identified in 39 of 40 clones, as shown in Fig. 1 . The one clone that did not have this YXN motif exhibited a YXQ motif. The amino acids asparagine and glutamine are structurally very similar, and peptides with a conservative substitution of this type would likely bind in a similar manner. The position between the Y and N residues was enriched for glutamic acid, aspartic acid, and alanine. Interestingly, Grb7 has been shown to bind to several cellular targets at sites containing phosphotyrosine (pY) residues within the motif YXN (12, 22-25, 27, 53) .
Individual peptide phage clones containing the YXN motif were tested in a reverse phage ELISA to determine the ability of the clones to bind to the SH2 domain of Grb7. GST alone and bovine serum albumin were used as control proteins. A Maxisorp 96-well plate was coated with an anti-GST polyclonal antibody to anchor the GST fusion proteins. Attachment of GST⅐Grb7 SH2 to the plate indirectly, via the anti-GST polyclonal antibody, was essential to detect binding of the peptide phage. Direct attachment of protein to the well did not give positive signals in the ELISA. This suggests that the SH2 portion of GST⅐Grb7 SH2 binds preferentially to the plastic, preventing interaction of the ligands with the SH2 domain. Fig.  2 shows the results of a reverse phage ELISA of a representative sample of clones isolated from the random peptide phage display library after three screens with Grb7 SH2. The binding of 40 clones was tested in a reverse phage ELISA, and all of the clones bound to Grb7 SH2 but not strongly (notice the scale of the Fig. 2 ELISA data) . Importantly, they did appear to bind to Grb7 specifically. Selectivity for the Grb7 SH2 was evident because relatively weak or undetectable binding was detected to the Grb2 SH2, which also targets peptides with a pYXN motif (61) . To increase the affinity and specificity of the peptides for Grb7, a biased library was created to enrich for the conserved motif.
Identification of Improved Grb7 SH2 Domain-binding Peptides by Screening a YXN-biased Peptide Phage Display Library-
The same fUSE5 system was used to create a phage display library biased for the conserved YXN motif. Phage display is a convenient system to enrich specific positions with one or many specific amino acids. Because the first screening with a random peptide phage display library resulted in a strong binding consensus, the biased library was designed to have 1) the same constrained structure as the random peptide library, 2) positions 10 and 12 fixed to display Y and N residues, respectively, and 3) position 11 biased for D, A, or E (50%). The biased library design is depicted as follows: X 4 -Cys-X 4 -Tyr 10 -(Asp/Ala/Glu/X) 11 -Asn 12 -X 3 -Cys-X 4 , referred to as the YXN-biased library. This library design biases positions 10, 11, and 12 in the displayed peptides with strongly conserved residues and allows for randomization in the other positions for further optimization. Three rounds of screening with this biased library resulted in excellent enrichment; 48 times more enriched phage bound to GST⅐Grb7 SH2 compared with binding to GST alone. The amino acid sequences of the peptides displayed by 40 clones were deduced after DNA sequencing of the inserts and are shown in Fig. 3 . Many of these clones appeared several times, as denoted in parentheses. The position between Tyr and Asn was designed to give a 50% chance for another amino acid to be in that position. However, the results indicate that the SH2 domain of Grb7 has a strong preference for Asp or Ala and less for Glu in this position.
Clones isolated from the YXN-biased library after screening with Grb7 SH2 were tested in a reverse phage ELISA to confirm binding to GST⅐Grb7 SH2. Fig. 4A shows that seven of the peptide clones identified from the YXN-biased library gave a strong and specific signal by phage ELISA to the Grb7 SH2 domain. These results demonstrate that the clones interact specifically with the Grb7 SH2 because no binding was detected to the Grb2 or Grb14 SH2 domains (Fig. 4A) . This is significant in the development of target-specific inhibitors because the Grb14 SH2 is closely related (67% amino acid identity), whereas the Grb2 SH2 exhibits an overlapping binding selectivity (pYXN). The specificity of these peptides was further 
FIG. 2.
Reverse phage ELISA for representative clones isolated from a random phage display library showing binding specific to the Grb7 SH2 domain. Peptide phage clones 1-8 are representative clones obtained from screening the random peptide library with Grb7 SH2. The peptide phage were purified from isolated clones to test their ability to bind to purified GST⅐Grb7 SH2, GST⅐Grb2, GST, and bovine serum albumin (BSA).
analyzed by investigating their interaction with a mutant form of the Grb7 SH2 in which two key residues at positions ␤D5 and ␤D6 are switched to corresponding residues in Grb14. This altered SH2 domain loses the ability to interact with the Grb7 binding site on ErbB2, pY1139 (53) . No binding to the mutated Grb7 SH2 was detected (Fig. 4A) , indicating that recognition of the EbB2 binding site and the synthetic peptides are dependent on the same SH2 specificity determinants. Two different peptide phage clones displaying Grb2-specific peptides (G1) (CE-LYENVGMYC) and G2-1 (GSGACGQLAYENVGWCEWTW) were used as controls for Grb7 specificity as shown in Fig. 4B to demonstrate that not all cyclic non-phosphorylated peptides containing a YXN motif bind to the SH2 domain of Grb7.
We focused further efforts on two of the seven clones isolated from the YXN-biased library shown to bind specifically to the SH2 domain of Grb7. These two clones, G7-8 and G7-18, demonstrated stronger signals repeatedly in the reverse phage ELISA compared with the other clones. Modified clones based on the G7-8 sequence were constructed to determine which amino acids were essential and if the peptides need to be cyclic. Our goal was to identify the lowest molecular weight, high affinity, non-phosphorylated peptides that retain specificity for the SH2 domain of Grb7. Peptides with these characteristics have the greatest chance of effectively inhibiting the function of Grb7 in vivo. G7-8 was modified as follows. 1) The four amino acids flanking the cysteines were eliminated; the product, CVWGYANDWLC, is referred to as G7-8-No Arms (NA). 2) The cysteines were replaced with structurally similar serine residues; the product, GVSNSVWGYANDWLSSDYS, is referred to as G7-8-Ser. 3) The cysteines were replaced also with valine residues, which are also similar in structure and charge to cysteines; the product, GVSNVVWGYANDWLVSDYS, is referred to as G7-8-Val; and 4) the cysteines were replaced with serines in combination with elimination of the four flanking amino acids; the product, SVWGYANDWLS, is referred to as G7-8-NA-Ser. The loss of binding activity after conservative substitutions for cysteines based on structure and/or charge is evidence that the peptide requires a cyclic structure for binding to Grb7 SH2. DNA oligos were created to encode for each of these G7-8 mutations, ligated into the fUSEV5 vector, and expressed as peptide phage. The four G7-8 peptide phage variants were tested in a reverse phage ELISA (Fig. 5) . The results indicate that the cysteines are essential for G7-8 to bind to the SH2 domain of Grb7 because G7-8-Ser and G7-8-Val do not bind to Grb7 SH2. This is evidence that G7-8 needs to be cyclic to maintain the ability to bind Grb7. In addition, elimination of the four amino acids at each end of the loop did not affect the ability of G7-8 to bind Grb7; therefore, the amino acids essential for binding are located between the two cysteine residues.
Synthetic Grb7-binding Peptides Bind in a Similar Manner as the Peptide Phage Clones-The relative ability of the free synthetic Grb7-binding peptides (G7-8 and G7-18) to inhibit the interaction between the Grb7-binding peptide phage and Grb7 SH2 was determined by a competitive reverse phage ELISA. Fig. 6 illustrates that the free peptides inhibit their respective phage-bound peptide clone from binding to Grb7 SH2 (Fig. 6 ). This demonstrates that the free peptide binds to the same site as the phage clone. In addition, the free synthetic G7-8 inhibits G7-18 peptide phage, demonstrating that both peptides are binding to the same site (Fig. 6B) . No inhibition was seen with the N1480 peptide, which is a PI3 kinase SH2-binding peptide (DpYVPML; Bachem), (data not shown). The exact inhibition constant cannot be determined using this method because the peptide phage clones display multiple copies of the peptide. In preparation for future in vitro experiments, the disulfide bond was replaced by a thioether bond because of the potential instability of disulfide bonds caused by the reducing environment inside a cell (3). Inhibition was also achieved with the thioether-containing peptides (G7-8NATE and G7-18NATE) but to a lesser extent than that seen with the disulfide containing peptides (Fig. 6) .
G7-18 Grb7-binding Peptide Blocks Grb7 SH2 Domain Function in Cell
Extracts-Two of the Grb7-binding peptides were tested for their ability to inhibit Grb7 from binding to the ErbB family of RTKs in whole cell extracts. Whole cell extracts were made from the cell line SK-BR-3, which overexpresses Grb7, ErbB2 and ErbB3. The cells were stimulated with heregulin-␤1 to increase the association of Grb7 with ErbB2 and ErbB3, as shown by Fiddes et al. (22) . Immunoprecipitation reactions were carried out with an anti-Grb7 polyclonal antibody followed by a Western blot with an anti-phosphotyrosine antibody to detect the p185-ErbB family of RTKs or the anti-ErbB3 polyclonal antibody. Fig. 7A shows that in the presence of G7-18NATE there was a loss of binding between Grb7 and the co-precipitated tyrosine-phosphorylated ErbB family of RTKs, as detected by the signal at 185 kDa. Fig. 7A also demonstrates that all reactions had an equal amount of Grb7 present, as detected by anti-Grb7 polyclonal antibody blotting. Densito -FIG. 4 . Reverse phage ELISA demonstrated the binding and specificity of clones identified from the YXNbiased library. A, seven peptide phage identified after screening the YXN Grb7-biased library give a strong signal by ELISA to the SH2 domain of Grb7 and not to the SH2 domains of Grb7 ␤D5-␤D6 (Grb7-bD5/bD6), Grb14, Grb2, and bovine serum albumin (BSA). n ϭ 5. B, Two different Grb2-binding peptides, which also have the YXN motif, do not bind to the SH2 domain of Grb7. n ϭ 5.
FIG. 5.
Analysis of modified G7-8 clones by reverse phage ELISA. The four G7-8 modified clones were: G7-8-NA, which had the four amino acids flanking the cysteines eliminated; G7-8-Ser, which had the cysteines replaced with serines; G7-8-Val, which had the cysteines replaced with valines; and G7-8-NA-Ser, which had the cysteines replaced with serines in combination with the elimination of the four flanking amino acids. The G7-8 peptide phage-modified clones were tested for their ability to bind to the GST⅐Grb7 SH2, GST⅐Grb7-␤D5/ ␤D6 SH2 mutant, GST⅐Grb14 SH2, GST⅐Grb2 SH2, GST, and bovine serum albumin (BSA) in a reverse phage ELISA (n ϭ 5). metric analysis of the autoradiographs was performed to further show that G7-18NATE is able to effectively inhibit Grb7 binding to the ErbB family of RTKs in a dose-dependent manner, shown in Fig. 7B . This analysis includes monitoring Grb2 association with the ErbB family of RTKs in the presence of G7-18NATE to test the specificity of G7-18NATE binding. As shown in the densitometric analysis in Fig. 7B , the presence of 1-100 M G7-18NATE has a negligible effect on the association of Grb2 compared with Grb7, co-precipitating with the tyrosine phosphorylated ErbB family of RTKs. Using the same analysis, G7-18NATE was found to inhibit the association of Grb7 with ErbB3 in a specific and dose-dependent manner (Fig. 8) .
As a negative control, immunoprecipitations were carried out in the presence of a non-phosphorylated peptide that corresponds to the Grb7 SH2 binding site on ErbB2 (Y1139), side-by-side with G7-18NATE. The Y1139 non-phosphorylated ErbB2 peptide showed no competition for Grb7 binding to the ErbB family of RTKs (data not shown). However, the phosphorylated version of the Y1139 peptide did compete (data not shown). This control also demonstrated that our non-phosphorylated peptide is more effective at binding to Grb7 SH2 than a peptide derived from the (non-phosphorylated) natural Grb7 binding site of ErbB2 and that the natural binding domain must be phosphorylated to bind Grb7 SH2.
This series of experiments demonstrates that the association of Grb7 with the ErbB family of RTKs, specifically ErbB3, can be inhibited by the small, non-phosphorylated peptide G7-18NATE. The same analysis was carried out with G7-8NATE, however this peptide was not able to inhibit the association of Grb7 with the ErbB family of RTKs.
DISCUSSION
The work described in this study identifies the first nonphosphorylated peptide to bind to the SH2 domain of Grb7.
Using a biased phage display library approach, we were able to significantly increase the ability of the peptide phage to bind to Grb7 SH2 and maintain specificity. This approach has been used successfully by other investigators in the identification of ligands to Grb2 (5), E-selectin (62), the erythropoeitin receptor (63) and the thrombopoietin receptor (64) . There were seven Grb7-binding peptide phage clones that, in a reverse phage ELISA, bound specifically to the SH2 domain of Grb7. In addition, these Grb7-specific clones were not able to bind the SH2 domain of Grb7 when the ␤D5 and ␤D6 residues, which are essential for binding to ErbB2, were mutated (53) . These data strongly indicate that the Grb7 peptides bind to the same site on the SH2 domain that binds to ErbB2. Importantly, there was no detectable binding to the SH2 domain of the closely related family member Grb14 or the SH2 domain of Grb2, which exhibits an overlapping binding selectivity.
The sequences of the seven Grb7-binding peptides from the biased YXN library have a strong consensus, exhibiting aromatic residues at Ϫ3 (relative to the core tyrosine) and ϩ4 and acidic residues at Ϫ2, ϩ1, ϩ3 (Fig. 9) . Acidic residues at the Ϫ2, ϩ1, and ϩ3 positions have been previously identified in Grb2-binding peptides (3, 5, 65, 66) , therefore, it is likely that these positions are not important for selectivity toward Grb7 versus Grb2. The selectivity may be due to the presence of aromatic residues at the position Ϫ3. These are not present in the previously identified Grb2-binding peptides (Fig. 9) . Interestingly, all of the peptides identified from the biased YXN library, which show no or low binding activity in an ELISA (clones G7-1, G7-5, G7-10, G7-11, G7-34), do not contain aromatic residues at Ϫ3. Binding selectivity for Grb7 over Grb2 was demonstrated for the ErbB3 autophosphorylation sites Tyr 1180 and Tyr 1243 (22) . Interestingly, the sequence of these sites exhibits a tyrosine at Ϫ2 (Fig. 9) , further supporting the hy- FIG. 6 . Competition reverse phage ELISA. The inhibition of G7-18 and G7-8-NA peptide phage binding to Grb7 SH2 with corresponding free synthetic peptides is shown. A, G7-8-NA peptide phage were added (10 6 transforming units/well) in the presence or absence of a competitor. Competitors were G7-8 and G7-8NATE free synthetic peptides. B, G7-18 peptide phage were added (10 6 transforming units/well) in the presence or absence of competitor. The competitors were G7-18, G7-18NATE, and G7-8 free synthetic peptides.
FIG. 7. G7-18NATE inhibits the association of Grb7 and not Grb2 with the ErbB family of RTKs.
A, the addition of G7-18NATE to lysates of heregulin-␤1-stimulated SKBR3 cells inhibits the co-immunoprecipitation of Grb7 and the ErbB family of RTKs. The immunoprecipitations were carried out with an anti-Grb7 polyclonal antibody followed by a Western blot. Top, probing was done with a horseradish peroxidaseconjugated anti-phosphotyrosine recombinant antibody to detect the associated ErbB family of RTKs (185 kDa). Bottom, probing was done with an anti-Grb7 polyclonal antibody as a loading control. B, a densitometric analysis of autoradiographs shows that G7-18NATE inhibits the association of Grb7 and not Grb2 with the ErbB family of RTKs in a dose-dependent manner.
pothesis that the Grb7 SH2 prefers an aromatic residue Nterminal to the core tyrosine. It is also worth noting that the Grb7-binding peptides select for aspartic acid at ϩ1, whereas the Grb2 peptides select for glutamic acid (Fig. 9) . Although both residues are acidic, this suggests that size constraints may play a role. Because glutamic and aspartic acids have similar properties it is likely that the preference for glutamic acid does not have a strong role in the selectivity of the peptides, but this will be investigated further. Because there is an overlap in the binding targets of different SH2 domains, having the ability to inhibit one SH2 domain specifically will be advantageous for developing target-specific therapeutics and understanding the exact role of Grb7.
Although it is possible that not all the peptides identified from the phage display libraries were in a cyclic form, the periplasm of E. coli, where the phage particles are assembled, is an oxidizing environment and favors the formation of a disulfide bond. The Grb7-binding clone, G7-8, required the cyclic structure as the preferred binding form demonstrated in Fig. 5 where the cysteines were substituted for either serines or valines. A Grb2-binding peptide identified by our laboratory was also shown to require the cyclic structure to bind the SH2 domain of Grb2 (3). Other groups have also shown that constrained peptides increase the potency of the ligand (67, 68) . The fact that the seven Grb7-binding clones have homologous sequences and G7-8 competes for G7-18 peptide clone binding in a competitive reverse phage ELISA (Fig. 6 ) suggests that these peptides are binding in a similar manner. Consequently, further analysis was not carried out for each individual clone.
Work by other groups using phage display technology have suggested that libraries of peptides with 3-4 random residues outside the disulfide loop are more effective at providing a source of ligands to certain targets (63, 64) . Our library incorporated these additional amino acids into the design; in the case of the Grb7-binding peptides, however, the four flanking amino acids on each side of the cysteines of the G7-8 peptide were not required for effective binding, as shown in Fig. 5 . This result allowed us to eliminate amino acids unnecessary for   FIG. 8. G7-18NATE inhibits the association of Grb7 with ErbB3. A, the addition of G7-18NATE to lysates of heregulin-␤1-stimulated SKBR3 cells inhibits the co-immunoprecipitation of Grb7 and ErbB3. The immunoprecipitations were carried out with an anti-Grb7 polyclonal antibody followed by a Western blot analysis. Top, probing was done with an anti-ErbB3 polyclonal antibody. Bottom, probing was done with an anti-Grb7 polyclonal antibody as a loading control. B, a densitometric analysis of autoradiographs shows that G7-18NATE inhibits the association of Grb7 with ErbB3 in a dose-dependent manner.
FIG. 9.
Consensus sequences of the Grb7-binding peptides identified from the random phage library and Grb7-binding and non-Grb7-binding peptides identified from the YXN-biased library compared with known Grb7 and Grb2 binding sites as well as previously identified Grb2-binding peptide consensus sequences. Consensus sequences denoted by * were deduced using ClustalW analysis.
effective binding to Grb7 and to further decrease the molecular weight of the peptide. This modification was also advantageous for developing thioether peptides where the amino acids flanking the cysteines create challenges during synthesis. Therefore, the peptides were synthesized without the four flanking amino acids adjacent to the cysteines for experiments testing the effects of the free peptides.
Non-phosphorylated peptides that bind to Grb7 have the advantage over other ligands to SH2 domains that possess a highly charged phosphate group. Phosphate groups can lead to poor cell penetration and predicted instability due to endogenous phosphatases. Because bacteria lack tyrosine kinase activity, the peptides on the phage are not expected to contain phosphorylated tyrosine residues (69) . Additional evidence that the peptide phage are not phosphorylated is provided by the fact that the synthetic peptides were not phosphorylated and yet were able to effectively compete with the peptide displayed on the phage for binding to Grb7. A recent publication (70) suggests that Grb7 SH2, in at least one case, may bind to a site (on RndI) without phosphorylation. All other known cellular targets of the Grb7 SH2 bind via a motif containing a phosphotyrosine.
In competition experiments the thioether peptides of G7-18 and G7-8 did not compete as well as the disulfide peptides (Fig.  4) . However, the thioether bond is more advantageous in the development of therapeutics targeting intracellular proteins because the reducing environment may affect the stability of a disulfide bond. Synthesizing other types of constrained peptides will be investigated in the future to increase the affinity in order to mimic the disulfide bond more closely. Importantly, despite the somewhat lower affinity, the thioether peptide G7-18NATE was able to effectively inhibit the association of Grb7 with the ErbB family of RTKs, specifically ErbB2 and ErbB3 (Figs. 7 and 8 ). Because ErbB2/ErbB3 heterodimers are not stable under our lysis conditions as shown by Fiddes et al. (22) , this suggests that G7-18NATE is able to inhibit the association of Grb7 with ErbB3 directly. As opposed to the observed inhibition of the association of Grb7 with its physiological binding partners, there was minimal inhibition of G7-18NATE on the association of Grb2 with ErbB family of RTKs. Using the same immunoprecipitation and densitometric analysis, the inhibition of G7-18NATE on the association of Grb2 to the ErbB family of RTKs did not increase as the concentration of peptide was increased from 1 M to 100 M. Therefore, the observed 10% inhibition is likely due to the margin of error within this type of assay. This finding is important because it demonstrates that the G7-18NATE as a free synthetic is able to specifically inhibit the Grb7 binding function.
Structural analysis of G7-18NATE compared with the binding of G7-8NATE to the Grb7 target will be important for understanding why G7-8NATE showed no effect on the binding of Grb7 with the ErbB family of RTKs (data not shown). Because G7-8 was able to compete with the G7-18 peptide phage (Fig. 6B) , these data suggest that the peptides bind in a similar manner; therefore, it is more likely that the inability of G7-8NATE to inhibit Grb7 binding to the ErbB family of RTKs is due to stability issues or the substituted thioether bond. Possible reasons why G7-8NATE peptide demonstrated no inhibition of Grb7 function, despite promising inhibitory effects by G7-18NATE, include the following. 1) G7-8NATE is not as stable as G7-18NATE under lysate conditions. 2) G7-8NATE is not able to bind to Grb7 with high affinity; or 3) G7-8NATE contains a thioether bond, which is of a different length than a disulfide bond.
Although the Grb7-binding peptides are not phosphorylated, we do not assume the peptides to be cell-permeable. In the further development of these lead Grb7 ligands it will be important to introduce biologically active peptides inside cells. There have been several reports describing specific membranetranslocating sequences that effectively deliver peptides to the cytoplasm and the nucleus (45) (46) (47) (48) . The hydrophobic regions of different signal peptide sequences have been used successfully to deliver peptides and full-length proteins as large as 40 kDa into living cells in a non-destructive manner (71) . Different membrane-translocating signal sequences have been derived from the Kaposi fibroblast growth factor, the HIV-1 Tat protein, and the homeodomains of Drosophila transcription factor Antennapedia. Another possible method of delivering peptide inhibitors into a cell is via encapsulation of peptide ligands in liposomes (72, 73) .
G7-18NATE will be further investigated as a lead compound to target cancers overexpressing Grb7. The set of peptide ligands identified here will be studied further to determine the effects of these peptides on the association of Grb7 with other oncogenic target molecules such as the platelet-derived growth factor receptor Tie/Tek and the focal adhesion kinase. These Grb7-specific peptides will be valuable in discerning the function of the Grb7 compared with other SH2-containing proteins and in developing a complete understanding of the signal transduction pathways where these molecules are involved. Structural and mutagenesis studies are being carried out with the Grb7-binding peptides complexed with the SH2 domain of Grb7 to better understand the binding and selectivity properties of these peptides. Additional studies are being carried out to develop a cell-permeable peptide to test the ability of the peptides to inhibit the migration and proliferation of cancer cells, which are potential downstream effects of the ErbB/Grb7 pathway.
